A randomized, single-blind evaluation of the Elixir DESyne BD novolimus-eluting coronary stent system with resorbable polylactide-based polymer compared with the Medtronic Endeavor zotarolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Novolimus (Primary) ; Zotarolimus
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Registrational; Therapeutic Use
- Acronyms EXCELLA-BD
- Sponsors Elixir Medical Corporation
- 03 Sep 2013 Results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
- 24 May 2013 2-year results reported in an Elixar Medical Corporation media release and presented at EuroPCR.
- 11 Mar 2013 Interim (6 and 24 month) results presented at the 62nd Annual Scientific Session of the American College of Cardiology.